Cagrilintide Peptide Research Compound & Study Overview Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Cagrilintide Semaglutide 2.4 2.4 Or 5 5 NuScience Peptides Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit